摘要
目的 剖析同步加量调强放疗用于乳腺癌保乳术后的临床作用。方法 将2020年1月-2022年6月本院接诊的180例乳腺癌保乳术后病人患者随机均分为试验组与对照组。试验组采取同步加量调强放疗，对照组行常规调强放疗。对比两组患者的功能状态（KPS评分）、生存质量（WHOQOL-BREF量表）及3年生存率。结果 治疗后，试验组KPS评分（79.57±4.05）分显著高于对照组的（71.47±4.63）分（P<0.05）。试验组在WHOQOL-BREF量表的各维度评分均显著高于对照组（P<0.05）。试验组3年生存率为86.67%，显著高于对照组的76.67%，但未见统计学差异（P＞0.05）。结论 在乳腺癌保乳术后应用同步加量调强放疗，能显著改善患者的功能状态与生存质量，并提高3年生存率，疗效确切，值得推广。
关键词： 同步加量调强放疗；乳腺癌；疗效；保乳术
Abstract
Objective To analyze the clinical effect of concurrent dose-modulated radiotherapy after breast-conserving surgery for breast cancer. Methods From January 2020 to June 2022, 180 patients who underwent breast-conserving surgery for breast cancer and were admitted to our hospital were randomly and equally divided into the experimental group and the control group. The experimental group received synchronous dose-increased intensity-modulated radiotherapy, while the control group received conventional intensity-modulated radiotherapy. The functional status (KPS score), quality of life (WHOQOL-BREF scale) and 3-year survival rate of the two groups of patients were compared. Results After treatment, the KPS score of the experimental group (79.57±4.05) points was significantly higher than that of the control group (71.47±4.63) points (P<0.05). The scores of each dimension of the WHOQOL-BREF scale in the experimental group were significantly higher than those in the control group (P<0.05). The 3-year survival rate of the experimental group was 86.67%, significantly higher than 76.67% of the control group, but no statistical difference was observed (P > 0.05). Conclusion The application of synchronous high-dose intensity-modulated radiotherapy after breast-conserving surgery for breast cancer can significantly improve the functional status and quality of life of patients, and increase the 3-year survival rate. The therapeutic effect is definite and worthy of promotion.
Key words： Synchronous dose-escalation intensity-modulated radiotherapy; Breast cancer; Therapeutic effect; Breast-conserving surgery
参考文献 References
[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] 毕晓峰, 宋翔, 王昕, 等. 早期乳腺癌保乳术后放疗与乳房切除术疗效比较的Meta分析[J]. 中华放射肿瘤学杂志, 2022, 31(4): 324-330.
[3] 马琴, 蒋倩, 景娜, 等. 早期乳腺癌保乳术后同步加量调强放疗与全乳调强放疗序贯电子线瘤床补量放疗的临床效果比较[J]. 肿瘤研究与临床, 2023, 35(11): 845-849.
[4] 国家癌症中心, 中国医师协会放射肿瘤治疗医师分会. 乳腺癌放射治疗质量控制指南（2022年版）[J]. 中华放射医学与防护杂志, 2022, 42(5): 321-328.
[5] Vicini F A, Cecchini R S, White J R, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial [J]. The Lancet, 2019, 394(10215): 2155-2164.
[6] 邵艳霞. 同步加量调强放疗对乳腺癌保乳术后患者近期生活质量及预后的影响分析[J]. 中国医疗设备, 2023, 38(7): 61-66.
[7] 刘娟, 王建, 李志明, 等. 乳腺癌保乳术后同步整合推量调强放疗的剂量学及近期疗效观察[J]. 中华放射肿瘤学杂志, 2021, 30(8): 789-794.
[8] 张颖, 赵快乐, 陈佳艺, 等. 早期乳腺癌保乳术后同步加量调强放疗的疗效与安全性研究进展[J]. 中国癌症杂志, 2022, 32(4): 350-356.
[9] Bekelman J E, Sylwestrzak M, Barron J, et al. Uptake and effectiveness of concurrent versus sequential boost intensity-modulated radiation therapy for breast cancer[J]. JAMA Oncology, 2021, 7(7): 1049-1051.
[10] 王淑莲, 李晔雄, 宋永文, 等. 乳腺癌保乳术后同步加量调强放疗与常规放疗的随机对照研究[J]. 中华放射肿瘤学杂志, 2020, 29(1): 1-6.